This is not just Dr McColl, it's the entire board and the strategic direction they are advising him to take.
There is no revenue (or indicated path to revenue) so all the SP can do rise on is good (and/or) new data and corporate activity.
Some of the board have got biotech deals done in previous lives - why has it been so lengthy with VLA?
It's not like it's bad timing or the industry is taking a downturn. This is one of the hottest sectors to be involved in right now. Something has to be in the happening in the background.
- Forums
- ASX - By Stock
- VLA
- Ann: VLA update on CAVATAK KEYTRUDA Combination trials - ESMO-VLA.AX
Ann: VLA update on CAVATAK KEYTRUDA Combination trials - ESMO-VLA.AX, page-13
-
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online